Trial Profile
A Phase 2a Study of Once Daily Intravenous Busulfan With Bortezomib, Followed by an Autologous Hematopoietic Stem Cell Transplant (HSCT) in Subjects With Relapsed Multiple Myeloma After Prior Autologous HSCT.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 04 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Apr 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 18 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.